Hopfield Jessica 4

What Happened Jessica Hopfield, a director of Editas Medicine (EDIT), received a grant of 51,700 derivative shares/options on June 17, 2026. The transaction is reported at $0.00 (derivative award), meaning no cash purchase or sale occurred at the time of grant. The award is scheduled to vest in full on June 17, 2027.

Key Details

• Transaction date: June 17, 2026; Form 4 filed June 22, 2026 (appears to be a late filing).
• Transaction type/code: A — Grant/award (derivative).
• Amount: 51,700 shares/options reported at $0.00 (derivative instrument); total cash value at grant not reported on the transaction line.
• Vesting: The award vests in full on June 17, 2027 (footnote F1).
• Shares owned after transaction: Not disclosed in the provided excerpt of the filing.
• Exercise price or other plan terms: Not specified in the transaction line provided.

Context This was an equity award (derivative/options) to a director—no shares were sold or purchased in the open market at the time of the grant. Such awards are commonly used for compensation and retention; they do not by themselves indicate buying or selling intent. Note the Form 4 was filed several days after the transaction date, which appears late under Section 16 reporting rules and may be noted by investors monitoring insider filing timeliness.